Novel therapies for cutaneous T-cell lymphoma: What does the future hold?

Emmanuella Guenova, Wolfram Hoetzenecker, Sima Rozati, Mitchell P. Levesque, Reinhard Dummer, Antonio Cozzio

Research output: Contribution to journalReview articlepeer-review

28 Scopus citations


Introduction: Cutaneous T-cell lymphomas (CTCLs) represent a group of extranodal non-Hodgkin lymphomas, of which mycosis fungoides (MF) is the most frequent. Standard therapeutic approaches are well established and often achieve stable disease. However, cure for MF is rare and thus novel therapies are needed. Areas covered: This review provides a discussion of the most promising new therapeutic approaches in the management of MF and other rare CTCLs. It includes targeted therapies with antibodies against surface molecules on malignant T cells (e.g., brentuximab), novel chemotherapeutic agents (e.g., pralatrexate), small-molecule compounds (e.g., panobinostat) and evidence of emerging targets in CTCLs (e.g., anti-IL-31). It also provides discussion of immune checkpoint inhibitors such as anti-PD1 that are worth considering in the treatment of leukaemic CTCL variants. Finally, it gives a brief overview of the possible use of stem-cell transplantation. Expert opinion: There is no doubt that progress has been made in the treatment of CTCLs with new, innovative and promising therapies approaching. However, there is still an urgent need to identify and test additional targets in well-designed clinical trials.

Original languageEnglish (US)
Pages (from-to)457-467
Number of pages11
JournalExpert Opinion on Investigational Drugs
Issue number4
StatePublished - Apr 2014
Externally publishedYes


  • Alemtuzumab
  • Brentuximab
  • Cutaneous lymphoma
  • Mycosis fungoides
  • Panobinostat
  • Pralatrexate
  • Sezary syndrome
  • Th1
  • Th2

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)


Dive into the research topics of 'Novel therapies for cutaneous T-cell lymphoma: What does the future hold?'. Together they form a unique fingerprint.

Cite this